Literature DB >> 29211406

Can preoperative neutrophil lymphocyte ratio predict malignancy in patients undergoing partial nephrectomy because of renal mass?

Sacit Nuri Gorgel1, Kutan Ozer1, Osman Kose1, Ahmet Selçuk Dindar1.   

Abstract

PURPOSE: To evaluate the importance of preoperative neutrophil lymphocyte ratio (NLR) predicting malignancy in patients who undergo partial nephrectomy due to renal mass.
MATERIALS AND METHODS: Seventy nine patients who underwent open partial nephrectomy for renal masses were included in this retrospective study. In preoperative routine blood tests, renal ultrasonography and contrast-enhanced computed tomography were performed for all patients. Preoperative neutrophil lymphocyte ratio were compared in patients with clear cell renal cell carcinoma (Group1, 65 patients) and benign lesions (Group 2, 14 patients). The predictive ability of NLR was analyzed by ROC curves and Youden Index method was used to identify the cut-off value for NLR.
RESULTS: The mean age of patients was 59.8±11.7 years in Group1 and 57.4±12.6 years in Group 2 (p=0.493). The mean tumor size was 3.8±1.2 cm in Group 1 and 3.3±1.0 cm in Group 2 (p=0.07). The median NLR was 2.48 (1.04) in Group 1 and 1.63 (0.96) in Group 2 (p<0.001). The area under a ROC curve was 0.799 (p<0.001).
CONCLUSIONS: Preoperative neutrophil lymphocyte ratio may predict renal masses that can not be distinguished radiologically. Our results must be confirmed by large and properly designed prospective, randomized trials. Copyright® by the International Brazilian Journal of Urology.

Entities:  

Keywords:  Carcinoma, Renal Cell; Lymphocytes; Neutrophils

Mesh:

Year:  2018        PMID: 29211406      PMCID: PMC5996777          DOI: 10.1590/S1677-5538.IBJU.2017.0225

Source DB:  PubMed          Journal:  Int Braz J Urol        ISSN: 1677-5538            Impact factor:   1.541


INTRODUCTION

Renal cell carcinoma (RCC) represents 2-3% of all cancers (1), with the highest incidence in Western countries. Over the last two decades until recently, the incidence of RCC increased by about 2% both worldwide and in Europe, although a continuing decrease has been observed in Denmark and Sweden (2). In 2012, there were approximately 84.400 new cases of RCC and 34.700 kidney cancer-related deaths in the European Union (3). In Europe, overall mortality rates for RCC increased up to the early 1990s, and stabilized or declined thereafter (4). Due to increased detection of tumors by ultrasound (US) and computed tomography (CT), the number of incidentally diagnosed RCCs has in-creased. These tumors are usually smaller and of lower stage (5-7). The relation between inflammation and tumor development and progression has been recognized in recent decades (8, 9). As a typical representative of inflammatory reactions, C-reactive protein (CRP) has been reported to be significantly associated with the prognosis of several cancers (10-14). Other systematic inflammation markers have been validated as predictive in various types of cancer (15-17). The neutrophil to lymphocyte ratio (NLR) is also a widely used inflammatory marker that is defined as the absolute neutrophil count divided by the absolute lymphocyte count, and can be easily determined from complete blood cell parameters (18). Unfortunately, radiological methods are still not sufficient for predicting malignancy. This can lead to unnecessary surgery in patients with benign renal masses. In this study, we investigated the importance of preoperative neutrophil lymphocyte ratio predicting malignancy in undistinguished radiological renal masses. This is the first study in the literature.

MATERIALS AND METHODS

Seventy nine patients who underwent open partial nephrectomy for renal masses were included in the study between 2006 and 2015. Patient data were analyzed retrospectively. In preoperative routine blood tests, renal ultrasonography and contrast-enhanced computed tomography were performed in all patients. NLR was compared in patients with clear cell RCC (Group 1, 65 patients) and benign lesions (Group 2, 14 patients). The predictive ability of NLR was analyzed by ROC curves and Youden Index method was used to identify the cut-off value for NLR.

Statistical Method

Normality distribution was investigated for all numeric variables. Categorical variables were described by frequencies and percentages and numeric variables were described by means and standard deviations or medians and interquartile ranges. The relationship between two categorical variables was tested by Chi-square test. Two independent means was compared by Student t test and two independent medians were compared by Mann Whitney U test. The predictive ability of NLR was analyzed by ROC curves and Youden Index method was used to identify the cut-off value for NLR. A p value less than 05 was accepted as statistically significant.

RESULTS

Mean age of patients was 59.8±11.7 years in Group 1 and 57.4±12.6 years in Group 2 (p=0.493). Mean tumor size was 3.8±1.2cm in Group 1 and 3.3±1.0cm in Group 2 (p=0.07). The median NLR was 2.48 (1.04) in group 1 and 1.63 (0.96) in group 2 (p<0.001). Both groups were similar in terms of sex and tumor side (Table-1) 14 patients had benign lesions. Eight patients had oncocytoma, 3 patients had calcified cyst, 2 patients had osseous metaplasia and 1 patient had angiomyolipoma.
Table 1

Descriptive characteristics of the patients.

Group 1 (n=65)Group 2 (n=14)p
Age(Mean±SD)59.8±11.757.4±12.60.493
Sex(n, %)
Male35 (53.8)6 (42.9)0.455
Female30 (46.2)8 (57.1)
Side(n, %)
Right35 (53.8)7 (50)0.794
Left30 (46.2)7 (50)
Size (cm)(Mean±SD)3.8±1.23.3±1.00.077
NLR(Median, IQR)2.48 (1.04)1.63 (0.96)<0.001

RCC = Renal cell carcinoma; SD = Standard deviation; IQR = Interquartile range

RCC = Renal cell carcinoma; SD = Standard deviation; IQR = Interquartile range Forty three (66.2%) of 65 patients had pT1a tumor and 22 (33.8%) of 65 patients had pT1b tumor 15 patients had grade 1 tumor, 46 patients had grade 2 tumor and 4 patients had grade 3 tumor. Optimal cut-off value of NLR was 1.725, with sensitivity of 93.8% and specificity 64.3% (Table-2).
Table 2

Cut-off values of NLR for malignancy.

Cut-off valuesSensitivity %Specificity %
Optimal1.72593.864.3
Max Sensitivity1.2751007.1
Max Specificity3.03529.2100

NLR = neutrophil lymphocyte ratio

NLR = neutrophil lymphocyte ratio The area under the ROC curve was 0.799 (p<0.001) (Figure-1). Predictive probability of NLR for tumor stage and grade were statistically insignificant (p=0.852) (Figures 2 and 3).
Figure 1

NLR predictive probability of the malignancy.

NLR = neutrophil lymphocyte ratio

Figure 2

NLR predictive probability of tumor stage.

NLR = neutrophil lymphocyte ratio

Figure 3

NLR predictive probability of the tumor grade.

NLR = neutrophil lymphocyte ratio

NLR predictive probability of the malignancy.

NLR = neutrophil lymphocyte ratio

NLR predictive probability of tumor stage.

NLR = neutrophil lymphocyte ratio

NLR predictive probability of the tumor grade.

NLR = neutrophil lymphocyte ratio

DISCUSSION

Increasing evidences support the involvement of systemic inflammation in cancer development and progression (9). It has been shown that, among the leukocytes in circulation, neutrophils increase and lymphocytes decrease as a systemic inflammatory response develops against the tumor. NLR has been used as an indicator of systemic inflammatory response (18). An elevated NLR reflects both a decreased lymphocyte mediated antitumor immune response and a increased neutrophil dependent inflammatory reaction. Both of these factors may contribute to aggressive tumor biology, cancer progression, and poor prognosis (19, 20). Despite recent progress in the identification of genetic, epigenetic and common molecular alterations in RCC (21), routine diagnostic and prognostic assessment of RCC currently relies on pathological tissue examination and traditional clinicopathological prognostic variables (22). The complexity of these molecular changes, as well as high costs of analyses, time-consuming preparation required and lack of evidence demonstrating how these newly discovered molecular markers influence diagnostic or therapeutic decisions, have rendered none of the markers available for routine testing. Recently, several serum biomarkers and hematological indices representative of inflammatory response, notably C reactive protein (CRP), fibrinogen, lymphocyte-monocyte ratio, neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio, have been demonstrated to be closely related to poor prognosis of patients with RCC (23-25). Therefore, NLR, defined as neutrophil counts divided by lymphocyte counts, is particularly noteworthy. Emerging evidences demonstrated that NLR showed its prognostic value in patients with colorectal cancer (26) and hepatocellular carcinoma (27). Patients with RCC with elevated levels of pretreatment NLR may be more likely to present a poorer clinical outcome (28). There are other laboratory markers of systemic inflammation reaction besides NLR, such as CRP (29) and modified Glasgow prognostic score (30, 31), with a prognostic role in patients with RCC. Also, gene polymorphisms (32) and biological markers (33, 34) are suggested to be predictors of prognosis in patients with RCC. Although NLR is easy to measure, conditions such as active infection, inflammatory diseases, smoking behavior or stress at the time of blood collection may affect it (35). In previous studies, it was demonstrated a relationship between poor prognosis and NLR. Unlike previous studies, we investigated the role of NLR in the malign-benign distinction. In the present study, we found that preoperative neutrophil lymphocyte ratio may predict renal masses that cannot be distinguished radiologically. This study has several limitations. First, the study was retrospective. Second, NLR could be affected by different conditions, especially undetected diseases such as chronic infection, chronic disease, and autoimmune disorders, such as rheumatic disease. Third, the number of patients was especially low in the benign group. Our results should be confirmed by prospective randomized studies with large population patients. If confirmed, preoperative NLR will be an important tool to prevent unnecessary surgeries.

CONCLUSIONS

Preoperative neutrophil lymphocyte ratio might predict renal masses that cannot be distinguished radiologically. Our results must be confirmed by large and properly designed prospective, randomized trials.
  34 in total

1.  Clinical variables for predicting metastatic renal cell carcinoma patients who might not benefit from cytoreductive nephrectomy: neutrophil-to-lymphocyte ratio and performance status.

Authors:  Yoshio Ohno; Jun Nakashima; Makoto Ohori; Ayako Tanaka; Takeshi Hashimoto; Tatsuo Gondo; Tadashi Hatano; Masaaki Tachibana
Journal:  Int J Clin Oncol       Date:  2013-01-09       Impact factor: 3.402

2.  Prognostic value of plasma fibrinogen levels in patients with localized upper tract urothelial carcinoma.

Authors:  Nobuyuki Tanaka; Eiji Kikuchi; Kazuhiro Matsumoto; Nozomi Hayakawa; Hiroki Ide; Akira Miyajima; So Nakamura; Mototsugu Oya
Journal:  BJU Int       Date:  2012-07-03       Impact factor: 5.588

3.  Validation of serum C-reactive protein (CRP) as an independent prognostic factor for disease-free survival in patients with localised renal cell carcinoma (RCC).

Authors:  Michela de Martino; Tobias Klatte; Christoph Seemann; Matthias Waldert; Andrea Haitel; Georg Schatzl; Mesut Remzi; Peter Weibl
Journal:  BJU Int       Date:  2013-03-15       Impact factor: 5.588

4.  Improving the accuracy of pre-operative survival prediction in renal cell carcinoma with C-reactive protein.

Authors:  S P K Jagdev; W Gregory; N S Vasudev; P Harnden; S Sim; D Thompson; J Cartledge; P J Selby; R E Banks
Journal:  Br J Cancer       Date:  2010-11-09       Impact factor: 7.640

5.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.

Authors:  J Ferlay; E Steliarova-Foucher; J Lortet-Tieulent; S Rosso; J W W Coebergh; H Comber; D Forman; F Bray
Journal:  Eur J Cancer       Date:  2013-02-26       Impact factor: 9.162

6.  Natural history of small renal cell carcinoma: evaluation of growth rate, histological grade, cell proliferation and apoptosis.

Authors:  Masanori Kato; Takashi Suzuki; Yasuyoshi Suzuki; Yoshio Terasawa; Hironobu Sasano; Yoichi Arai
Journal:  J Urol       Date:  2004-09       Impact factor: 7.450

7.  The changing pattern of kidney cancer incidence and mortality in Europe.

Authors:  Fabio Levi; Jacques Ferlay; Carlotta Galeone; Franca Lucchini; Eva Negri; Peter Boyle; Carlo La Vecchia
Journal:  BJU Int       Date:  2008-01-30       Impact factor: 5.588

8.  Clinical utility of the Glasgow Prognostic Score in patients undergoing curative nephrectomy for renal clear cell cancer: basis of new prognostic scoring systems.

Authors:  G W A Lamb; M Aitchison; S Ramsey; S L Housley; D C McMillan
Journal:  Br J Cancer       Date:  2011-12-13       Impact factor: 7.640

9.  Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients.

Authors:  Sandra Steffens; Astrid Köhler; Raphael Rudolph; Hendrik Eggers; Christoph Seidel; Martin Janssen; Gerd Wegener; Mark Schrader; Markus A Kuczyk; Andres J Schrader
Journal:  BMC Cancer       Date:  2012-09-08       Impact factor: 4.430

10.  External validation of the modified Glasgow prognostic score for renal cancer.

Authors:  Caroline G Tai; Timothy V Johnson; Ammara Abbasi; Lindsey Herrell; Wayne B Harris; Omer Kucuk; Daniel J Canter; Kenneth Ogan; John G Pattaras; Peter T Nieh; Viraj A Master
Journal:  Indian J Urol       Date:  2014-01
View more
  1 in total

1.  Role of 18F-FDG-PET/CT in Combination With Neutrophil-Lymphocyte Ratio in the Diagnosis of Upper Urinary Tract Lesion: Can We Accurately Predict Malignant Tumor?

Authors:  Zhi-Bin Ke; Xiao-Dan Lin; Ye-Hui Chen; Yun-Zhi Lin; Shao-Hao Chen; Shao-Ming Chen; Yu Chen; Yong Wei; Qing-Shui Zheng; Xue-Yi Xue; Xiao-Dong Li; Ning Xu
Journal:  Front Oncol       Date:  2021-09-22       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.